A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Clinical trial NCT06090266 · RECRUITING

Trial details

NCT number: NCT06090266
Sponsor: OncoResponse, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Cancer Tumor, Solid Malignant Neoplasm Metastatic Cancer Advanced Solid Tumor Cutaneous Melanoma Non-small Cell Lung Cancer

Start date: 2023-10-24
Primary completion: 2026-08-01
Enrollment: 168

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.